ES2880718T3 - Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas - Google Patents

Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas Download PDF

Info

Publication number
ES2880718T3
ES2880718T3 ES15709149T ES15709149T ES2880718T3 ES 2880718 T3 ES2880718 T3 ES 2880718T3 ES 15709149 T ES15709149 T ES 15709149T ES 15709149 T ES15709149 T ES 15709149T ES 2880718 T3 ES2880718 T3 ES 2880718T3
Authority
ES
Spain
Prior art keywords
cells
hla
units
scu
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15709149T
Other languages
English (en)
Spanish (es)
Inventor
Patrick Henno
Gonzalez Martin Villalba
Zhao Yang Lu
Jean-François Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMERCELL Sas
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Original Assignee
EMERCELL Sas
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EMERCELL Sas, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier filed Critical EMERCELL Sas
Application granted granted Critical
Publication of ES2880718T3 publication Critical patent/ES2880718T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
ES15709149T 2014-03-07 2015-03-09 Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas Active ES2880718T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305332 2014-03-07
PCT/EP2015/054837 WO2015132415A1 (en) 2014-03-07 2015-03-09 Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease

Publications (1)

Publication Number Publication Date
ES2880718T3 true ES2880718T3 (es) 2021-11-25

Family

ID=50277168

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15709149T Active ES2880718T3 (es) 2014-03-07 2015-03-09 Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas

Country Status (8)

Country Link
US (1) US20170073637A1 (enExample)
EP (1) EP3114215B1 (enExample)
JP (2) JP6775426B2 (enExample)
CN (1) CN106164256B (enExample)
CA (1) CA2941519C (enExample)
DK (1) DK3114215T3 (enExample)
ES (1) ES2880718T3 (enExample)
WO (1) WO2015132415A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
KR20180086204A (ko) * 2015-11-05 2018-07-30 글리코스템 떼라퓨틱스 비.브이. 면역치료법에 사용하기 위한 조성물
EP3411414A4 (en) * 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
DK3755347T3 (da) * 2018-02-21 2025-08-04 Univ Texas Universelle antigenpræsenterende celler og anvendelser deraf
KR20210052494A (ko) 2018-08-27 2021-05-10 아피메트 게엠베하 항체 구조물이 사전 로드된 동결 보존된 nk 세포
WO2020152661A1 (ja) * 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
JP2021035400A (ja) * 2020-12-07 2021-03-04 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
CA2703428A1 (en) * 2010-05-11 2011-11-11 Mcgill University Health Center Pooled cord blood units
WO2012009422A1 (en) * 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
KR101447546B1 (ko) * 2011-03-03 2014-10-08 한국생명공학연구원 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
JP5840876B2 (ja) * 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
WO2014123879A1 (en) * 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta

Also Published As

Publication number Publication date
CA2941519C (en) 2022-09-06
DK3114215T3 (da) 2021-06-21
JP2017508479A (ja) 2017-03-30
US20170073637A1 (en) 2017-03-16
WO2015132415A1 (en) 2015-09-11
CN106164256A (zh) 2016-11-23
EP3114215A1 (en) 2017-01-11
JP6775426B2 (ja) 2020-10-28
JP2020114248A (ja) 2020-07-30
CN106164256B (zh) 2021-08-10
CA2941519A1 (en) 2015-09-11
EP3114215B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
ES2880718T3 (es) Células NK de sangre del cordón umbilical combinadas y sus usos para el tratamiento del cáncer y enfermedades infecciosas crónicas
JP7072808B2 (ja) 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
ES2860974T3 (es) Método para cultivar células asesinas naturales utilizando células T
ES2871349T3 (es) Expansión selectiva y controlada de células NK educadas
ES2877108T3 (es) Activación de linfocitos infiltrantes de médula en condiciones hipóxicas alternantes con normóxicas
EP2725100B1 (en) Method for amplifying nk cells
EP3000876B1 (en) Method for preparing nk cells
JP2025156345A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP5431146B2 (ja) 免疫学的寛容および調節性前駆細胞
US20140050710A1 (en) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
WO2017042393A1 (en) Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
US20130005035A1 (en) Methods for generating t lymphocytes from hematopoietic stem cells
US20250375520A1 (en) Production of immune cells
KR20120054018A (ko) 일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
HK1171949A (en) Pharmaceutical composition containing transiently surviving ctl
HK1190432B (en) Method for amplifying nk cells
EP3347454A1 (en) Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease